Neonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1 Inhibition

source : nejm.org

Raphaela Goldbach-Mansky, M.D., Natalie J. Dailey, M.D., Scott W. Canna, M.D., Ana Gelabert, M.S.N., Janet Jones, B.S.N., Benjamin I. Rubin, M.D., H. Jeffrey Kim, M.D., Carmen Brewer, Ph.D., Christopher Zalewski, M.A., Edythe Wiggs, Ph.D., Suvimol Hill, M.D., Maria L. Turner, M.D., Barbara I. Karp, M.D., Ivona Aksentijevich, M.D., Frank Pucino, Pharm.D., Scott R. Penzak, Pharm.D., Margje H. Haverkamp, M.D., Leonard Stein, M.D., Barbara S. Adams, M.D., Terry L. Moore, M.D., Robert C. Fuhlbrigge, M.D., Ph.D., Bracha Shaham, M.D., James N. Jarvis, M.D., Kathleen O’Neil, M.D., Richard K. Vehe, M.D., Laurie O. Beitz, M.D., Gregory Gardner, M.D., William P. Hannan, M.D., Robert W. Warren, M.D., Ph.D., William Horn, M.D., Joe L. Cole, M.D., Scott M. Paul, M.D., Philip N. Hawkins, M.D., Tuyet Hang Pham, B.S., Christopher Snyder, B.S., Robert A. Wesley, Ph.D., Steven C. Hoffmann, M.S., Steven M. Holland, M.D., John A. Butman, M.D., Ph.D., and Daniel L. Kastner, M.D., Ph.D.

ABSTRACT

Background Neonatal-onset multisystem inflammatory disease is characterized by fever, urticarial rash, aseptic meningitis, deforming arthropathy, hearing loss, and mental retardation. Many patients have mutations in the cold-induced autoinflammatory syndrome 1 (CIAS1) gene, encoding cryopyrin, a protein that regulates inflammation.

Methods We selected 18 patients with neonatal-onset multisystem inflammatory disease (12 with identifiable CIAS1 mutations)to receive anakinra, an interleukin-1–receptor antagonist(1 to 2 mg per kilogram of body weight per day subcutaneously).In 11 patients, anakinra was withdrawn at three months untila flare occurred. The primary end points included changes inscores in a daily diary of symptoms, serum levels of amyloidA and C-reactive protein, and the erythrocyte sedimentationrate from baseline to month 3 and from month 3 until a diseaseflare.

Results All 18 patients had a rapid response to anakinra, withdisappearance of rash. Diary scores improved (P<0.001) andserum amyloid A (from a median of 174 mg to 8 mg per liter),C-reactive protein (from a median of 5.29 mg to 0.34 mg perdeciliter), and the erythrocyte sedimentation rate decreasedat month 3 (all P<0.001), and remained low at month 6. Magneticresonance imaging showed improvement in cochlear and leptomeningeallesions as compared with baseline. Withdrawal of anakinra uniformlyresulted in relapse within days; retreatment led to rapid improvement.There were no drug-related serious adverse events.

Conclusions Daily injections of anakinra markedly improved clinical and laboratory manifestations in patients with neonatal-onset multisystem inflammatory disease, with or without CIAS1 mutations. (ClinicalTrials.gov number, NCT00069329 [ClinicalTrials.gov] .)

Refensi

  1. Prieur AM, Griscelli C. Arthropathy with rash, chronic meningitis, eye lesions, and mental retardation. J Pediatr 1981;99:79-83. [CrossRef][Web of Science][Medline]
  2. Database of human genes and genetic disorders: OMIM (Online Mendelian Inheritance in Man). Bethesda, Md.: National Center for Biotechnology Information, 2006. (Accessed July 14, 2006, at http://www.ncbi.nlm.nih.gov/entrez/Omim.)
  3. Prieur AM, Griscelli C, Lampert F, et al. A chronic, infantile, neurological, cutaneous and articular (CINCA) syndrome: a specific entity analysed in 30 patients. Scand J Rheumatol Suppl 1987;66:57-68.
  4. Feldmann J, Prieur AM, Quartier P, et al. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet 2002;71:198-203.
  5. Aksentijevich I, Nowak M, Mallah M, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 2002;46:3340-3348.
  6. Stojanov S, Kastner DL. Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr Opin Rheumatol 2005;17:586-599.
  7. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001;29:301-305.
  8. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004;20:319-325.
  9. Manji GA, Wang L, Geddes BJ, et al. PYPAF1, a PYRIN-containing Apaf1-like protein that assembles with ASC and regulates activation of NF-kappa B. J Biol Chem 2002;277:11570-11575.
  10. Wang L, Manji GA, Grenier JM, et al. PYPAF7, a novel PYRIN-containing Apaf1-like protein that regulates activation of NF-kappa B and caspase-1-dependent cytokine processing. J Biol Chem 2002;277:29874-29880.
  11. O’Connor W Jr, Harton JA, Zhu X, Linhoff MW, Ting JP. Cutting edge: CIAS1/cryopyrin/PYPAF1/NALP3/CATERPILLER 1.1 is an inducible inflammatory mediator with NF-kappaB suppressive properties. J Immunol 2003;171:6329-6333
  12. Yu JW, Wu J, Zhang Z, et al. Cryopyrin and pyrin activate caspase-1, but not NF-kappa B, via ASC oligomerization. Cell Death Differ 2006;13:236-249. [CrossRef][Web of Science][Medline]
  13. Kanneganti TD, Ozoren N, Body-Malapel M, et al. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 2006;440:233-236. [CrossRef][Medline]
  14. Grenier JM, Wang L, Manji GA, et al. Functional screening of five PYPAF family members identifies PYPAF5 as a novel regulator of NF-kappaB and caspase-1. FEBS Lett 2002;530:73-78. [CrossRef][Web of Science][Medline]
  15. Dowds TA, Masumoto J, Zhu L, Inohara N, Nunez G. Cryopyrin-induced interleukin 1beta secretion in monocytic cells: enhanced activity of disease-associated mutants and requirement for ASC. J Biol Chem 2004;279:21924-21928. [Free Full Text]
  16. Lovell DJ, Bowyer SL, Solinger AM. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis Rheum 2005;52:1283-1286. [CrossRef][Web of Science][Medline]
  17. Frenkel J, Wulffraat NM, Kuis W. Anakinra in mutation-negative NOMID/CINCA syndrome: comment on the articles by Hawkins et al and Hoffman and Patel. Arthritis Rheum 2004;50:3738-3739. [CrossRef][Web of Science][Medline]
  18. Granel B, Serratrice J, Disdier P, Weiller PJ. Dramatic improvement with anakinra in a case of chronic infantile neurological cutaneous and articular (CINCA) syndrome. Rheumatology (Oxford) 2005;44:689-690.
  19. Wilkins J, Gallimore JR, Tennent GA, et al. Rapid automated enzyme immunoassay of serum amyloid A. Clin Chem 1994;40:1284-1290. [Free Full Text]
  20. Hoffmann SC, Kampen RL, Amur S, et al. Molecular and immunohistochemical characterization of the onset and resolution of human renal allograft ischemia-reperfusion injury. Transplantation 2002;74:916-923. [CrossRef][Web of Science][Medline]
  21. Aganna E, Martinon F, Hawkins PN, et al. Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum 2002;46:2445-2452. [Erratum, Arthritis Rheum 2002;46:3398.] [CrossRef][Web of Science][Medline]
  22. Hawkins PN, Lachmann HJ, McDermott MF. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 2003;348:2583-2584. [Free Full Text]
  23. Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004;50:607-612. [CrossRef][Web of Science][Medline]
  24. Russell EJ, Geremia GK, Johnson CE, et al. Multiple cerebral metastases: detectability with Gd-DTPA-enhanced MR imaging. Radiology 1987;165:609-617. [Free Full Text]
  25. Brekenfeld C, Foert E, Hundt W, Kenn W, Lodeann KP, Gehl HB. Enhancement of cerebral diseases: how much contrast agent is enough? Comparison of 0.1, 0.2, and 0.3 mmol/kg gadoteridol at 0.2 T with 0.1 mmol/kg gadoteridol at 1.5 T. Invest Radiol 2001;36:266-275. [CrossRef][Web of Science][Medline]
  26. Frosch MP, Anthony DC, de Girolami U. The central nervous system. In: Kumar V, Abbas AK, Fausto N, eds. Robbins and Cotran pathologic basis of disease. 7th ed. Philadelphia: Elsevier Saunders, 2005:1347-420.
  27. Gripshover NM, Ellner JJ. Chronic meningitis. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 5th ed. Philadelphia: Churchill Livingstone, 2000:998-1000.
  28. Luheshi GN. Cytokines and fever: mechanisms and sites of action. Ann N Y Acad Sci 1998;856:83-89. [CrossRef][Web of Science][Medline]
  29. Kagiwada K, Chida D, Sakatani T, et al. Interleukin (IL)-6, but not IL-1, induction in the brain downstream of cyclooxygenase-2 is essential for the induction of febrile response against peripheral IL-1alpha. Endocrinology 2004;145:5044-5048. [Free Full Text]
  30. Li S, Ballou LR, Morham SG, Blatteis CM. Cyclooxygenase-2 mediates the febrile response of mice to interleukin-1beta. Brain Res 2001;910:163-173. [CrossRef][Web of Science][Medline]
  31. Benveniste EN. Inflammatory cytokines within the central nervous system: sources, function, and mechanism of action. Am J Physiol 1992;263:C1-C16.
  32. Dinarello CA. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol 1998;16:457-499. [Medline]
  33. Anderson JP, Mueller JL, Rosengren S, et al. Structural, expression, and evolutionary analysis of mouse CIAS1. Gene 2004;338:25-34. [CrossRef][Web of Science][Medline]
  34. Breder CD, Dinarello CA, Saper CB. Interleukin-1 immunoreactive innervation of the human hypothalamus. Science 1988;240:321-324. [Free Full Text]
  35. Vitkovic L, Bockaert J, Jacque C. “Inflammatory” cytokines: neuromodulators in normal brain? J Neurochem 2000;74:457-471. [CrossRef][Web of Science][Medline]
  36. Dinarello CA. Blocking IL-1 in systemic inflammation. J Exp Med 2005;201:1355-1359. [Free Full Text]

This article has been cited by other articles:

  • Aksentijevich, I., Masters, S. L., Ferguson, P. J., Dancey, P., Frenkel, J., van Royen-Kerkhoff, A., Laxer, R., Tedgard, U., Cowen, E. W., Pham, T.-H., Booty, M., Estes, J. D., Sandler, N. G., Plass, N., Stone, D. L., Turner, M. L., Hill, S., Butman, J. A., Schneider, R., Babyn, P., El-Shanti, H. I., Pope, E., Barron, K., Bing, X., Laurence, A., Lee, C.-C. R., Chapelle, D., Clarke, G. I., Ohson, K., Nicholson, M., Gadina, M., Yang, B., Korman, B. D., Gregersen, P. K., van Hagen, P. M., Hak, A. E., Huizing, M., Rahman, P., Douek, D. C., Remmers, E. F., Kastner, D. L., Goldbach-Mansky, R. (2009). An Autoinflammatory Disease with Deficiency of the Interleukin-1-Receptor Antagonist. NEJM 360: 2426-2437 [Abstract] [Full Text]
  • Dinarello, C. A. (2009). Interleukin-1β and the Autoinflammatory Diseases. NEJM 360: 2467-2470 [Full Text]
  • Lachmann, H. J., Lowe, P., Felix, S. D., Rordorf, C., Leslie, K., Madhoo, S., Wittkowski, H., Bek, S., Hartmann, N., Bosset, S., Hawkins, P. N., Jung, T. (2009). In vivo regulation of interleukin 1{beta} in patients with cryopyrin-associated periodic syndromes. JEM 206: 1029-1036 [Abstract] [Full Text]
  • Nold-Petry, C. A., Nold, M. F., Zepp, J. A., Kim, S.-H., Voelkel, N. F., Dinarello, C. A. (2009). IL-32-dependent effects of IL-1{beta} on endothelial cell functions. Proc. Natl. Acad. Sci. USA 106: 3883-3888 [Abstract] [Full Text]
  • Netea, M. G., Nold-Petry, C. A., Nold, M. F., Joosten, L. A. B., Opitz, B., van der Meer, J. H. M., van de Veerdonk, F. L., Ferwerda, G., Heinhuis, B., Devesa, I., Funk, C. J., Mason, R. J., Kullberg, B. J., Rubartelli, A., van der Meer, J. W. M., Dinarello, C. A. (2009). Differential requirement for the activation of the inflammasome for processing and release of IL-1{beta} in monocytes and macrophages. Blood 113: 2324-2335 [Abstract] [Full Text]
  • Lord, C. A., Savitsky, D., Sitcheran, R., Calame, K., Wright, J. R., Ting, J. P.-Y., Williams, K. L. (2009). Blimp-1/PRDM1 Mediates Transcriptional Suppression of the NLR Gene NLRP12/Monarch-1. J. Immunol. 182: 2948-2958 [Abstract] [Full Text]
  • Dinarello, C. A. (2009). Targeting the Pathogenic Role of Interleukin 1{beta} in the Progression of Smoldering/Indolent Myeloma to Active Disease. Mayo Clin Proc. 84: 105-107 [Full Text]
  • Granell, M., Urbano-Ispizua, A., Pons, A., Arostegui, J. I., Gel, B., Navarro, A., Jansa, S., Artells, R., Gaya, A., Talarn, C., Fernandez-Aviles, F., Martinez, C., Rovira, M., Carreras, E., Rozman, C., Juan, M., Yague, J., Montserrat, E., Monzo, M. (2008). Common variants in NLRP2 and NLRP3 genes are strong prognostic factors for the outcome of HLA-identical sibling allogeneic stem cell transplantation. Blood 112: 4337-4342 [Abstract] [Full Text]
  • Sidiropoulos, P I, Goulielmos, G, Voloudakis, G K, Petraki, E, Boumpas, D T (2008). Inflammasomes and rheumatic diseases: evolving concepts. Ann Rheum Dis 67: 1382-1389 [Abstract] [Full Text]
  • Li, S. C. (2008). Characteristics of Patients With Systemic-Onset JIA Who Respond to Anti-Interleukin-1 Treatment. AAP Grand Rounds 20: 32-33 [Full Text]
  • Botsios, C., Sfriso, P., Furlan, A., Punzi, L., Dinarello, C. A. (2008). Resistant Behcet Disease Responsive to Anakinra. ANN INTERN MED 149: 284-286 [Full Text]
  • Kadhim, H. J., Duchateau, J., Sebire, G. (2008). Cytokines and Brain Injury: Invited Review. J Intensive Care Med 23: 236-249 [Abstract]
  • Yao, Q., Furst, D. E. (2008). Autoinflammatory diseases: an update of clinical and genetic aspects. Rheumatology (Oxford) 47: 946-951 [Abstract] [Full Text]
  • Kastbom, A., Verma, D., Eriksson, P., Skogh, T., Wingren, G., Soderkvist, P. (2008). Genetic variation in proteins of the cryopyrin inflammasome influences susceptibility and severity of rheumatoid arthritis (The Swedish TIRA project). Rheumatology (Oxford) 47: 415-417 [Abstract] [Full Text]
  • Farasat, S., Aksentijevich, I., Toro, J. R. (2008). Autoinflammatory Diseases: Clinical and Genetic Advances. Arch Dermatol 144: 392-402 [Abstract] [Full Text]
  • Maksimovic, L., Stirnemann, J., Caux, F., Ravet, N., Rouaghe, S., Cuisset, L., Letellier, E., Grateau, G., Morin, A.-S., Fain, O. (2008). New CIAS1 mutation and anakinra efficacy in overlapping of Muckle-Wells and familial cold autoinflammatory syndromes. Rheumatology (Oxford) 47: 309-310 [Abstract] [Full Text]
  • Saito, M., Nishikomori, R., Kambe, N., Fujisawa, A., Tanizaki, H., Takeichi, K., Imagawa, T., Iehara, T., Takada, H., Matsubayashi, T., Tanaka, H., Kawashima, H., Kawakami, K., Kagami, S., Okafuji, I., Yoshioka, T., Adachi, S., Heike, T., Miyachi, Y., Nakahata, T. (2008). Disease-associated CIAS1 mutations induce monocyte death, revealing low-level mosaicism in mutation-negative cryopyrin-associated periodic syndrome patients. Blood 111: 2132-2141 [Abstract] [Full Text]
  • Singh-Grewal, D., Chaitow, J., Aksentijevich, I., Christodoulou, J. (2007). Coexistent MEFV and CIAS1 mutations manifesting as familial Mediterranean fever plus deafness. Ann Rheum Dis 66: 1541-1541 [Full Text]
  • Kuijk, L. M, Govers, A. M A P, Hofhuis, W. J D, Frenkel, J. (2007). Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra. Ann Rheum Dis 66: 1545-1546 [Full Text]
  • Kaizer, E. C., Glaser, C. L., Chaussabel, D., Banchereau, J., Pascual, V., White, P. C. (2007). Gene Expression in Peripheral Blood Mononuclear Cells from Children with Diabetes. J. Clin. Endocrinol. Metab. 92: 3705-3711 [Abstract] [Full Text]
  • Lauro, C. F., Goldbach-Mansky, R., Schmidt, M., Quezado, Z. M. N. (2007). The Anesthetic Management of Children with Neonatal-Onset Multi-System Inflammatory Disease. Anesth. Analg. 105: 351-357 [Abstract] [Full Text]
  • Zeft, A., Bohnsack, J. F (2007). Cryopyrin-associated autoinflammatory syndrome: a new mutation. Ann Rheum Dis 66: 843-844 [Full Text]
  • Duncan, J. A., Bergstralh, D. T., Wang, Y., Willingham, S. B., Ye, Z., Zimmermann, A. G., Ting, J. P.-Y. (2007). Cryopyrin/NALP3 binds ATP/dATP, is an ATPase, and requires ATP binding to mediate inflammatory signaling. Proc. Natl. Acad. Sci. USA 104: 8041-8046 [Abstract] [Full Text]
  • Kummer, J. A., Broekhuizen, R., Everett, H., Agostini, L., Kuijk, L., Martinon, F., van Bruggen, R., Tschopp, J. (2007). Inflammasome Components NALP 1 and 3 Show Distinct but Separate Expression Profiles in Human Tissues Suggesting a Site-specific Role in the Inflammatory Response. J. Histochem. Cytochem. 55: 443-452
  • Remick, D. G. (2007). Pathophysiology of Sepsis. Am. J. Pathol. 170: 1435-1444
  • Mastronardi, C., Whelan, F., Yildiz, O. A., Hannestad, J., Elashoff, D., McCann, S. M., Licinio, J., Wong, M.-L. (2007). Caspase 1 deficiency reduces inflammation-induced brain transcription. Proc. Natl. Acad. Sci. USA 104: 7205-7210
  • Larsen, C. M., Faulenbach, M., Vaag, A., Volund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., Donath, M. Y. (2007). Interleukin-1-Receptor Antagonist in Type 2 Diabetes Mellitus. NEJM 356: 1517-1526
  • Jin, Y., Mailloux, C. M., Gowan, K., Riccardi, S. L., LaBerge, G., Bennett, D. C., Fain, P. R., Spritz, R. A. (2007). NALP1 in Vitiligo-Associated Multiple Autoimmune Disease. NEJM 356: 1216-1225
  • (2006). Lucina. Arch. Dis. Child. 91: 1048-1048
  • Fister, K. (2006). What’s new in the other general journals. BMJ 333: 387-388
  • (2006). New Therapy for Neonatal-Onset Multisystem Inflammatory Disease. Journal Watch Dermatology 2006: 1-1

 

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s